Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Combination of TMB and CNA Stratifies Prognostic and Predictive Responses to Immunotherapy Across Metastatic Cancer
Li Liu, Xue Bai, Jian Wang, et al.
Clinical Cancer Research (2019) Vol. 25, Iss. 24, pp. 7413-7423
Open Access | Times Cited: 267

Showing 1-25 of 267 citing articles:

Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response
Dongrui Wang, Xianlin Wu, Yingli Sun
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 293
Tumour mutational burden as a biomarker for immunotherapy: Current data and emerging concepts
Jean-David Fumet, Caroline Truntzer, Mark Yarchoan, et al.
European Journal of Cancer (2020) Vol. 131, pp. 40-50
Open Access | Times Cited: 201
Development and interpretation of a pathomics-based model for the prediction of microsatellite instability in Colorectal Cancer
Rui Cao, Fan Yang, Si-Cong Ma, et al.
Theranostics (2020) Vol. 10, Iss. 24, pp. 11080-11091
Open Access | Times Cited: 175
Identification of the pyroptosis‑related prognostic gene signature and the associated regulation axis in lung adenocarcinoma
Wanli Lin, Ying Chen, Bomeng Wu, et al.
Cell Death Discovery (2021) Vol. 7, Iss. 1
Open Access | Times Cited: 175
Which role for predictors of response to immune checkpoint inhibitors in hepatocellular carcinoma?
Alessandro Rizzo, Antonio Cusmai, Gennaro Gadaleta‐Caldarola, et al.
Expert Review of Gastroenterology & Hepatology (2022) Vol. 16, Iss. 4, pp. 333-339
Closed Access | Times Cited: 79
Molecular Characteristics, Clinical Significance, and Cancer Immune Interactions of Angiogenesis-Associated Genes in Gastric Cancer
Qing Xin, Wenjing Xu, Shengli Liu, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 77
Liquid biopsy at the frontier in renal cell carcinoma: recent analysis of techniques and clinical application
Mingyang Li, Lei Li, Jianyi Zheng, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 51
Immunotherapy for advanced-stage squamous cell lung cancer: the state of the art and outstanding questions
Yibei Wang, Mohammed Safi, Fred R. Hirsch, et al.
Nature Reviews Clinical Oncology (2025) Vol. 22, Iss. 3, pp. 200-214
Closed Access | Times Cited: 3
An immune-related gene signature for predicting survival and immunotherapy efficacy in hepatocellular carcinoma
Yifei Dai, Weijie Qiang, Kequan Lin, et al.
Cancer Immunology Immunotherapy (2020) Vol. 70, Iss. 4, pp. 967-979
Open Access | Times Cited: 124
Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy in Hepatocellular Carcinoma: Where Do We Stand?
Alessandro Rizzo, Angela Dalia Ricci, Alessandro Di Federico, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 97
PD-L1, TMB, and other potential predictors of response to immunotherapy for hepatocellular carcinoma: how can they assist drug clinical trials?
Alessandro Rizzo, Angela Dalia Ricci
Expert Opinion on Investigational Drugs (2021) Vol. 31, Iss. 4, pp. 415-423
Closed Access | Times Cited: 91
Artificial Intelligence for Histology-Based Detection of Microsatellite Instability and Prediction of Response to Immunotherapy in Colorectal Cancer
Lindsey A Hildebrand, Colin Pierce, Michael J. Dennis, et al.
Cancers (2021) Vol. 13, Iss. 3, pp. 391-391
Open Access | Times Cited: 72
The Predictive Value of Tumor Mutation Burden on Clinical Efficacy of Immune Checkpoint Inhibitors in Melanoma: A Systematic Review and Meta-Analysis
Biao Ning, Yixin Liu, Miao Wang, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 56
Identification and Validation of Cuproptosis-Related Prognostic Signature and Associated Regulatory Axis in Uterine Corpus Endometrial Carcinoma
Yun Chen
Frontiers in Genetics (2022) Vol. 13
Open Access | Times Cited: 52
An immune subtype-related prognostic signature of hepatocellular carcinoma based on single-cell sequencing analysis
Jiaheng Xie, Liang Chen, Qingmei Sun, et al.
Aging (2022) Vol. 14, Iss. 7, pp. 3276-3292
Open Access | Times Cited: 48
Programmed Death Ligand-1 and Tumor Mutation Burden Testing of Patients With Lung Cancer for Selection of Immune Checkpoint Inhibitor Therapies: Guideline From the College of American Pathologists, Association for Molecular Pathology, International Association for the Study of Lung Cancer, Pulmonary Pathology Society, and LUNGevity Foundation
Lynette M. Sholl, Mark M. Awad, Upal Roy, et al.
Archives of Pathology & Laboratory Medicine (2024) Vol. 148, Iss. 7, pp. 757-774
Open Access | Times Cited: 17
Biomarkers and computational models for predicting efficacy to tumor ICI immunotherapy
Yurong Qin, Miaozhe Huo, Xingwu Liu, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 16
Identification of ferroptosis-related lncRNAs for predicting prognosis and immunotherapy response in non-small cell lung cancer
Lin Yuan, Shengguo Sun, Qinhu Zhang, et al.
Future Generation Computer Systems (2024) Vol. 159, pp. 204-220
Closed Access | Times Cited: 13
PD-1/PD-L1 immune checkpoint blockade in breast cancer: research insights and sensitization strategies
Menglei Jin, Jun Fang, Jiakuan Peng, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 12
Exploiting tumor aneuploidy as a biomarker and therapeutic target in patients treated with immune checkpoint blockade
Liam F. Spurr, Sean P. Pitroda
npj Precision Oncology (2024) Vol. 8, Iss. 1
Open Access | Times Cited: 11
Identification of KRAS mutation-associated gut microbiota in colorectal cancer and construction of predictive machine learning model
Zigui Huang, Xiaoliang Huang, Yili Huang, et al.
Microbiology Spectrum (2024) Vol. 12, Iss. 5
Open Access | Times Cited: 9
SLC7A11 is a potential therapeutic target and prognostic biomarker correlated with immune cell infiltration in cervical cancer
Mutangala Muloye Guy, Tingting Bian, Lingwei Sun, et al.
Discover Oncology (2025) Vol. 16, Iss. 1
Open Access | Times Cited: 1
Differential expression of the MYC‐Notch axis drives divergent responses to the front‐line therapy in central and peripheral extensive‐stage small‐cell lung cancer
Libo Luo, Rui Xia, Shiqi Mao, et al.
MedComm (2025) Vol. 6, Iss. 3
Open Access | Times Cited: 1
An Integrative Pan-Cancer Analysis Revealing LCN2 as an Oncogenic Immune Protein in Tumor Microenvironment
Wen‐Xiu Xu, Jian Zhang, Yu-Ting Hua, et al.
Frontiers in Oncology (2020) Vol. 10
Open Access | Times Cited: 68
Tumor copy-number alterations predict response to immune-checkpoint-blockade in gastrointestinal cancer
Zhihao Lü, Huan Chen, Shuang Li, et al.
Journal for ImmunoTherapy of Cancer (2020) Vol. 8, Iss. 2, pp. e000374-e000374
Open Access | Times Cited: 57
Page 1 - Next Page

Scroll to top